Compare Summit Therapeutics Inc (SMMT) vs TeraWulf Inc (WULF) Price & Performance

Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.

The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.

WULF trades at $13.65, down 5.21% today, amid a bearish technical signal and volatile AI infrastructure sector sentiment. The company reported a net loss of $661.42 million in 2025 with a negative net income margin of -392.64%, while revenue was $168.46 million. Recent news highlights its pivot to AI data centers, with stock movements influenced by sector-wide trends and analyst coverage.

Outlook remains speculative with high valuation ratios (P/S 35.73, P/B 46.24) and persistent losses posing risks, but 100% analyst buy ratings and a $34.92 consensus price target suggest long-term growth potential from AI hosting contracts. Key risks include execution challenges and competitive pressures in the evolving AI infrastructure space.